Welcome to our dedicated page for Nkarta SEC filings (Ticker: NKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nkarta, Inc. (NASDAQ: NKTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nkarta is a clinical-stage biotechnology and biopharmaceutical company developing engineered, allogeneic, off-the-shelf NK cell therapies for autoimmune diseases, and its SEC filings offer structured insight into how it reports financial results, clinical progress, and key risks to investors.
Nkarta’s recent Form 8-K filings include press releases announcing quarterly financial results, where the company discusses research and development expenses, general and administrative expenses, net loss, and its cash position. These 8-Ks also reference Nkarta’s status as an emerging growth company and point to more detailed risk factor sections in its Form 10-K and Form 10-Q reports.
Through its periodic filings, Nkarta describes the clinical development of its lead NK cell therapy candidate NKX019, including its use in Ntrust-1 and Ntrust-2 autoimmune disease trials and investigator-sponsored studies. The company’s filings outline factors such as limited operating history, lack of approved products, dependence on NKX019, clinical trial timing, manufacturing complexity for CAR NK therapies, and reliance on third parties, which it identifies as key business and development risks.
On Stock Titan, Nkarta’s SEC filings are updated as new documents are posted to the EDGAR system. AI-powered summaries help explain the main points of lengthy filings, highlight changes from prior reports, and surface items such as financial condition discussions and risk factor updates. Users can quickly review 8-Ks related to earnings announcements and use the platform’s tools to understand how Nkarta’s disclosures connect to its NK cell therapy pipeline and autoimmune disease focus.
Nkarta, Inc. reported an equity award to its President, Mahmood Nadir, in the form of both restricted stock units and stock options. On 01/06/2026, he received 80,000 shares of Common Stock as Restricted Stock Units, which are scheduled to vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock.
On the same date, he was also granted a stock option covering 160,000 shares of Common Stock at an exercise price of $ 1.93 per share, expiring on 01/05/2036. This option is scheduled to vest in 48 equal monthly installments following January 14, 2026, contingent on continued service. After these transactions, he directly beneficially owned 173,376 shares of Common Stock and 160,000 derivative securities.
Nkarta, Inc. reported an insider equity award for Chief Executive Officer and director Paul J. Hastings. On January 6, 2026, he received 94,000 shares of Common Stock in the form of Restricted Stock Units, granted at a price of $0. These RSUs vest in four equal annual installments beginning on January 14, 2027, with each RSU convertible into one share of Common Stock.
On the same date, Hastings was also granted a stock option for 562,000 shares of Common Stock at an exercise price of $1.93 per share, with no cost reported for the grant itself. This option is scheduled to vest in 48 equal monthly installments following January 14, 2026. After these transactions, he beneficially owned 416,069 shares of Common Stock directly, along with the 562,000 stock options. The share total includes 2,000 shares acquired under Nkarta’s 2020 Employee Stock Purchase Plan on November 30, 2025.
Nkarta, Inc. reported Q3 2025 results. Net loss was $21.7M or $0.29 per share, driven by operating expenses of $27.3M (R&D $20.2M; G&A $7.1M). Other income of $5.6M included $1.7M received for Employee Retention Credit claims, with $1.5M recognized in other income and $0.2M in interest. Year‑to‑date net loss was $76.7M.
Balance sheet and liquidity. Cash, cash equivalents, restricted cash and investments totaled $316.5M as of September 30, 2025 (cash and equivalents $60.1M, short‑term investments $222.2M, long‑term investments $31.4M). Total assets were $427.2M and stockholders’ equity $337.9M. Operating cash use year‑to‑date was $67.1M, while investing activities provided $99.2M. Management believes available funds will meet obligations for at least twelve months from the filing date. The company recorded a $0.8M impairment to right‑of‑use assets and ended with lease liabilities of $76.6M. A March workforce reduction (~34%) carried total severance of $5.4M; $0.7M remained accrued at quarter‑end. Clinically, deep B‑cell depletion was observed with Flu/Cy lymphodepletion, and the iDSMB authorized enrollment in the second dose‑escalation cohort.
Nkarta, Inc. furnished an update on its business by announcing that it issued a press release with financial results for the third quarter ended September 30, 2025. The company provided this update via a current report and attached the press release as Exhibit 99.1 titled “Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights.”
The disclosure states that the information, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf engineered NK cell therapies, with lead program NKX019 targeting CD19 for autoimmune diseases. The company continues multiple Phase 1 and investigator-sponsored trials while reprioritizing its pipeline and modifying lymphodepleting conditioning for ongoing studies.
For the three months ended June 30, 2025 Nkarta reported a net loss of $22.98 million and for the six months a net loss of $54.96 million. Research and development was $20.78 million in the quarter and $44.95 million for six months; total operating expenses were $27.19 million in the quarter. As of June 30, 2025 the company had an accumulated deficit of $599.2 million and reported $334.0 million of cash, cash equivalents, restricted cash and investments, which management believes is sufficient to fund operations for at least 12 months.
Operational actions include a March 26, 2025 reduction in force of 53 positions (~34% of workforce) with related severance of approximately $5.4 million, deprioritization of certain programs, and the appointment of Shawn Rose, M.D., Ph.D., as Chief Medical Officer effective June 23, 2025. The balance sheet shows total assets of $448.3 million and operating lease liabilities of $78.5 million.
Nkarta, Inc. furnished a press release announcing its financial results for the second quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Current Report on Form 8-K. The Form 8-K also includes a Cover Page Interactive Data File as Exhibit 104. The filing states the Item 2.02 disclosure (including Exhibit 99.1) is being furnished and shall not be deemed "filed" under the Exchange Act nor incorporated by reference into filings under the Securities Act or the Exchange Act unless the company expressly states otherwise.
The filing identifies the registrant as a Delaware corporation (Commission File Number 001-39370; EIN 47-4515206), lists its principal executive office in South San Francisco, California, and shows the company’s common stock trades as NKTX on the Nasdaq Global Select Market. The report is signed by Nadir Mahmood as President.
Nkarta reported a significant insider transaction involving Chief Medical Officer and Head of R&D, Shawn Marshall Rose. On June 23, 2025, Rose was granted stock options to purchase 500,000 shares of common stock at an exercise price of $1.75 per share.
The stock options have a structured vesting schedule:
- 25% of the options vest on July 23, 2026
- Remaining 75% vest in 36 equal monthly installments following June 23, 2026
- Options expire on June 22, 2035
This grant suggests a long-term retention strategy for a key executive, with the low exercise price potentially indicating recent stock price challenges or an incentive-focused compensation structure. The substantial size of the grant (500,000 shares) reflects the senior leadership position and importance of the R&D function to the company.
Form 3 Initial Statement of Beneficial Ownership filed for Nkarta (NKTX) on June 28, 2025, reporting the beneficial ownership status of Shawn Marshall Rose, who has been appointed as the company's Chief Medical Officer and Head of Research & Development.
Key details:
- Filing Date: June 28, 2025
- Event Date: June 23, 2025
- Location: South San Francisco, CA
- Filing Type: Individual filing
- Current Holdings: No securities beneficially owned
This Form 3 indicates that the executive currently holds no derivative or non-derivative securities in the company. The filing was signed by Bridgette Housley as Attorney-in-Fact on June 25, 2025, and includes a Power of Attorney as Exhibit 24.
Nkarta, Inc. (NKTX) – Form 4 Insider Transaction Overview
CEO and Director Paul J. Hastings disclosed the sale of 1,790 common shares on 06/18/2025 at a weighted-average price of $1.79. The transaction was automatically executed to satisfy tax-withholding obligations triggered by the vesting and settlement of Restricted Stock Units and therefore was not a discretionary sale. Following the sale, Hastings continues to beneficially own 320,069 shares, which includes 2,000 shares purchased under Nkarta’s 2020 Employee Stock Purchase Plan on 05/31/2025.
No derivative securities were acquired or disposed of, and no additional transactions were reported. Given the small size of the sale—roughly 0.56% of the executive’s total holdings—the filing appears routine and does not signal any change in corporate strategy, financial position, or insider sentiment.